Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Allan, E.K."'
Autor:
Basil D'Souza, Sasha R Fehily, Allan E.K. Lim, Felicity C Martin, Linda S Yang, Penelope A McKelvie
Publikováno v:
JGH Open: An Open Access Journal of Gastroenterology and Hepatology
JGH Open, Vol 4, Iss 3, Pp 345-350 (2020)
JGH Open, Vol 4, Iss 3, Pp 345-350 (2020)
In 1991, Genta and Haggitt described four patients with segmental ischemic colitis caused by idiopathic myointimal hyperplasia in the small mesenteric veins (IMHMV). There are now 33 published cases of IMHMV in the literature; however, this condition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa4f884744e6603fd9ae09703bcbf19
http://europepmc.org/articles/PMC7273708
http://europepmc.org/articles/PMC7273708
Publikováno v:
In Journal of Molecular Structure: THEOCHEM 2006 761(1):177-193
Publikováno v:
In Journal of Organometallic Chemistry 2001 633(1):149-156
Autor:
Penelope A McKelvie, Allan E.K. Lim
Publikováno v:
Pathology. 51:S90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd0542d3cfc2829ce9fd0aec57b1db80
https://doi.org/10.1016/j.pathol.2018.12.239
https://doi.org/10.1016/j.pathol.2018.12.239
Publikováno v:
Pathology. 51:S90
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a97b22f3147654313a5392f7dc14369
https://doi.org/10.1016/j.pathol.2018.12.238
https://doi.org/10.1016/j.pathol.2018.12.238
Autor:
Allan E.K. Lim, Shona Hendry
Publikováno v:
Pathology. 50:S79
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5cba5460c3e563534799544ac769f74c
https://doi.org/10.1016/j.pathol.2017.12.208
https://doi.org/10.1016/j.pathol.2017.12.208
Autor:
Lim, Allan E.K., McKelvie, Penelope A.
Publikováno v:
In Pathology February 2019 51 Supplement 1:S90-S90
Publikováno v:
In Pathology February 2019 51 Supplement 1:S90-S90
Autor:
Lim, Allan E.K., Hendry, Shona
Publikováno v:
In Pathology February 2018 50 Supplement 1:S79-S79
Chronic myeloid leukaemia (CML) is maintained by a rare population of tyrosine kinase inhibitor (TKI)-insensitive malignant stem cells. Our long-term aim is to find a BcrAbl-independent drug that can be combined with a TKI to improve overall disease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::22a8625304a04bf52b5272d52ffe1d52
https://eprints.gla.ac.uk/53224/1/53224.pdf
https://eprints.gla.ac.uk/53224/1/53224.pdf
